Curriculum vitae

Date of birth: 08.02.1992

University Education
2021 - Dr. med., “Summa cum laude”, Institute of Molecular Oncology
2018 - Approbation
2018 - 2^nd state examination in Medicine, Philipps-University Marburg
2017 - 1^st state examination in Medicine, Philipps-University Marburg

Employment and Positions
2021 - present   Junior Research Group Leader “Translational Breast Cancer Research”
2020 - present   Clinician Scientist and admission to the Clinician Scientist program (SUCCESS-Program) of the
           Philipps-University Marburg
2019 - present   Assistant Doctor in the Department of Gynecology and Obstetrics at the University Hospital Marburg

Awards and Honors
2021 - Von Behring-Röntgen young talent award for outstanding achievements in medical research
2011-2019 - Scholarship from the German National Academic Foundation

Publications
PubMed

Research Focus
Based on novel insights in tumor biology within the last years, a plethora of different molecular cancer targeted therapies (e.g. CDK4/6- and PI3Kinase-Inhibitors) have entered clinical practice and improved the therapy of HR+, HER2- and PIK3CA^mut metastasized breast cancer. However, the phenotypic plasticity and inherent genomic instability allow tumors, to rapidly evolve drug resistant subclones as a cause of intrinsic or acquired therapy resistance and eventually lead to tumor relapse and therapy failure.
As a key driver of cancer drug resistance, increased mTOR signaling is associated with resistance to various targeted drugs. mTORC1 functions hereby as a central integrator of oncogenic signaling cascades and impedes the initiation of the cellular self-digestion process, named autophagy. Given the central role of autophagy in cellular energy homeostasis, activation of mTORC1 signaling suppresses autophagy and thereby deprives cells of a powerful survival mechanism to compensate metabolic perturbation induced by various compounds targeting cancer metabolism. Thus, resistant cancer cells with aberrant mTORC1 signaling activity suffer severe energy stress and induce apoptosis.
Based on these findings current research in the group is exploring the translational potential of metabolic drugs for overcoming treatment resistance in breast cancer.

Funding
Stiftung P.E. Kempkes (01/2021)
UKGM Research Grant (03/2022 MR)
UCT Frankfurt-Marburg
SUCCESS Program of the Philipps-University Marburg